SCHEMBL11964162

SCHEMBL11964162

COc1ccc(-c2cc(Nc3nc(Sc4ccc(NC(=O)C5CC5)cc4)nc(N4CCN(C)CC4)n3)n[nH]2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 8/20 0.70
▸ AURKB Q96GD4 8/20 0.70
▸ RIPK1 Q13546 3/20 0.70
▸ PLK4 O00444 3/20 0.58
▸ AURKC Q9UQB9 3/20 0.57
▸ ABL1 P00519 2/20 0.57
▸ BCR P11274 2/20 0.57
▸ SRC P12931 2/20 0.57
▸ BMPR1B O00238 1/20 0.57
▸ STK25 O00506 1/20 0.57
▸ RIOK3 O14730 1/20 0.57
▸ CHEK1 O14757 1/20 0.57
▸ GAK O14976 1/20 0.57
▸ MUSK O15146 1/20 0.57
▸ EPHB6 O15197 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ MAP3K13 O43283 1/20 0.57
▸ DAPK3 O43293 1/20 0.57
▸ MAP3K7 O43318 1/20 0.57
▸ NUAK1 O60285 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11964171 0.92 AURKA (0.75) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL11964157 0.91 AURKA (0.71) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL11964450 0.91 AURKA (0.73) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL10294716 0.86 AURKA (0.92) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL10294937 0.86 AURKA (0.79) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL11964156 0.85 AURKA (0.70) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL16900359 0.85 AURKA (0.53) AURKAAURKBRIPK1CHEK1NTRK1
SCHEMBL10294926 0.84 AURKA (0.76) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL10294858 0.84 AURKA (0.76) AURKAAURKBRIPK1PLK4AURKC
SCHEMBL11964856 0.84 AURKB (0.70) AURKAAURKBRIPK1PLK4AURKC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9078902-B2 Triazine derivatives and their therapeutical applications NANTBIOSCIENCE, INC. (US) 2015-07-14 — — US disclosed
US-20120196860-A1 Triazine derivatives and their therapeutical applications CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196860-A1 Triazine derivatives and their therapeutical applications MAP3K2, MAP3K5, MAP4K2 AURKA 877/4885AURKB 756/4885RIPK1 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback